Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA advisory committee
Pharma
FDA challenges broad use of PD-1 drugs in stomach cancer
The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu
Sep 24, 2024 2:30pm
Intercept's Ocaliva nod in danger after negative FDA adcomm vote
Sep 16, 2024 10:40am
Ocaliva's fate looks bleak after FDA releases new briefing docs
Sep 11, 2024 4:58pm
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
Amid concerns, FDA approves AZ's Imfinizi in perioperative NSCLC
Aug 16, 2024 10:51am
AZ set to face tough questions on Imfinzi expansion bid in NSCLC
Jul 24, 2024 8:29am
